Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Top-line results from STEP UP T2D are expected in the next few months, according to Novo Nordisk. For more information: Steven B. Heymsfield, MD, FTOS, can be reached at [email protected] .

Semaglutide 7.2mg is also being investigated in the phase 3 STEP UP T2D trial (ClinicalTrials.gov Identifier: NCT05649137) in 512 adults with obesity and type 2 diabetes to demonstrate weight loss ...

Shares of Novo Nordisk (NYSE:NVO) rose 1% following news that the company has submitted an application to the European Medicines Agency (EMA) to approve a higher dose of its obesity treatment, Wegovy.

A single protocol-defined DLT occurred in 1 participant after their SC 50 mg step-up dose who developed grade 3 TRAEs (ALT and AST increased) that recovered to grade 1 in 8 days. ICANS occurred in 2 ...